Phaseline

Companies › Crystalys Therapeutics

Crystalys Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 3, 1 Phase 2, 1 Phase 4; Cardiovascular, Metabolic and endocrine; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dotinurad
Solute carrier family 22 member 12 inhibitor
SLC22A12Phase 3Gout; Tophaceous Gout; Hyperuricemia or GoutJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07535034DotinuradPhase 2GoutMetabolic and endocrineJul 2027
NCT06834230DotinuradPhase 4Hyperuricemia or GoutCardiovascularJul 2027
NCT07089875DotinuradPhase 3GoutMetabolic and endocrineNov 2027
NCT07089888DotinuradPhase 3Tophaceous GoutMetabolic and endocrineDec 2027

Targets

SLC22A12 (1)

Companies with the same targets

Jiangsu HengRui Medicine

Companies built like this

Lexicon Pharmaceuticals Vincentage Pharma Fresenius Kabi Pulmovant EBI Anti Sepsis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.